Daniel Nigh

Practice Areas
  • Pharmaceutical Drugs
  • Medical Devices
  • Orthopedic Devices
  • Cryptocurrency Exchange Bankruptcy
  • Mass Torts
  • Product Liability
  • Personal Injury
  • Car Accident/Motorcycle Accident/Trucking Accident
  • Multi District Litigation
  • Juris Doctor, Stetson University College of Law, Gulfport, FL, 2003 Honors: Magna Cum Laude
  • Yerrid, Steve C. Award for Outstanding Trial Attorney
  • Florida Southern College in Lakeland, FL
  • Phi Mu Alpha Kappa Alpha Order Member
  • Phi Mu Alpha President
  • Phi Chi Treasurer
  • Bachelor of Science in Psychology with Business Minor

Last Updated: March 27, 2024

Daniel Nigh, a founding partner of Nigh Goldenberg Raso & Vaughn, is our litigation co-counsel on Ozempic, Wegovy, and Rybelsus cases. Daniel is well versed in multidistrict litigation and is currently Co-Lead Counsel for the Valsartan lawsuit (MDL 2875). Nigh Goldenberg Raso & Vaughn has over 50 years of combined experience pursuing recoveries for clients that were injured by multinational corporations.

Originally born in Los Angeles, California, Daniel Nigh spent most of his time living in the small town of Polk City, Florida.
Daniel first attended Florida Southern College in Lakeland Florida. After graduating magna cum laude with a Bachelor of Science in psychology and minors in business administration and math, Daniel went on to earn his JD at Stetson Law. Once again, Daniel received magna cum laude recognition while earning his law degree. While earning his degree, Daniel was employed as a law clerk at Brasfield, Fuller, Freeman & O’Hern.

Daniel Nigh previously filed the first Benicar lawsuit in the nation alongside Rayna Kessler and was a key player in the case’s inception. Daniel was also in charge of the committee for discovery. An international settlement of $385 million resulted from the Benicar litigation. In addition to the Benicar case, Daniel has served on esteemed panels like the DePuy ASR science and experts committee, co-chaired the third-party discovery committee, and participated in the Bair Hugger litigation’s bellwether committee. Mr. Nigh has also given presentations on a broad range of subjects, such as Bair Hugger, Abilfy, Benicar, Valsartan, Zantac, Xeljanz, hip implant litigation, knee implant lawsuits, and general mass tort litigation. Additionally, he has written published multiple works for the FJA Journal on subjects like Valsartan, Zantac, Benicar, hip and knee implant lawsuits, and more.

Mr. Nigh is currently at the forefront of the Semaglutide litigation against defendants such as Novo Nordisk, the manufacturer of Ozempic and Wegovy.

Honors and Awards:

  • The National Trial Lawyers – Top 100 in 2023
  • The National Trial Lawyers – Top 40 under 40 in 2017
  • SuperLawyers – Rising Star in 2016